Haploidentical stem cell transplant with post-transplantation cyclophosphamide and mini-dose methotrexate in children | Zendy

Diego Medina | Zendy; Mayra Estacio | Zendy; María Rosales | Zendy; Eliana Manzi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Haploidentical stem cell transplant with post-transplantation cyclophosphamide and mini-dose methotrexate in children

Author(s) -

Diego Medina,

Mayra Estacio,

María Rosales,

Eliana Manzi

Publication year - 2020

Publication title -

hematology/oncology and stem cell therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.666

H-Index - 22

eISSN - 1658-3876

pISSN - 2589-0646

DOI - 10.1016/j.hemonc.2020.01.003

Subject(s) - medicine , fludarabine , busulfan , methotrexate , cyclophosphamide , cumulative incidence , gastroenterology , transplantation , graft versus host disease , hemorrhagic cystitis , melphalan , surgery , total body irradiation , interquartile range , hematopoietic stem cell transplantation , mycophenolic acid , chemotherapy

Haploidentical stem cell transplantation (haplo-SCT) is an option for patients without human leukocyte antigen-matched related or unrelated donor. Post-transplantation cyclophosphamide (PTCy) is an effective method of graft versus host disease (GVHD) prophylaxis and permits the use of T-cell replete grafts in settings were ex vivo manipulation is not feasible.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research